China: Origin Agritech Forms GMO Soybean Development and Commercialization Collaboration

Origin Agritech Ltd., an agriculture technology company, has announced that the company has entered into a collaboration agreement with Biotechnology Research Institute (BRI), a division of Chinese Academy of Agriculture Sciences (CAAS) to expand collaborations in GMO soybean research and commercialization. In addition to glyphosate tolerance G2-epsps gene, which BRI developed and Origin has global exclusive commercial rights in corn, soybean, and other major crops, Origin and BRI will expand their collaboration to develop dicamba tolerance, drought tolerance, and salt-alkaline tolerance GMO soybean varieties by using three BRI newly developed and patented genes.

Over the years, Origin has been cooperating with BRI in developing various GM traits, including GMO phytase corn, glyphosate tolerance corn, and double stacked insect resistance and glyphosate tolerance corn.  The phytase corn trait received bio-safety approval in 2009. A number of elite phytase commercial corn hybrids have been developed and pending for variety bio-safety approval. Glyphosate tolerance corn and double stacked insect resistance/glyphosate tolerance corn have completed most trails and are in the government approval process. By using G2-epsps gene, BRI developed GMO glyphosate tolerance soybean, which received a bio-safety certificate on July 15, 2020.

Advertisement

The new collaboration agreement deepens Origin’s cooperation with BRI and mainly focuses on related research and commercialization of GMO soybean. BRI will focus on fundamental research and provide technical support to Origin on GMO soybean product development and global commercialization.

Continue reading at PR Newswire.

Top Articles
ADAMA Reports Fourth Quarter and Full Year 2023 Results

Hide picture